Pre-Hepatectomy Assessment of Bile Transporter Expression by Gadoxetic Acid-Enhanced MRI in a Rat Model of Liver Cirrhosis

REFERENCES

• Rahbari NN, Garden OJ, Padbury R, et al. Posthepatectomy liver failure: A definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery. 2011;149:713–724.
   PubMed Web of Science ®Google Scholar
• Schreckenbach T, Liese J, Bechstein WO, et al. Posthepatectomy liver failure. Digest Surg. 2012;29:79–85.
   PubMed Web of Science ®Google Scholar
• Wibmer A, Prusa AM, Nolz R, et al. Liver failure after major liver resection: Risk assessment by using preoperative Gadoxetic acid-enhanced 3-T MR imaging. Radiology. 2013;269:777–786.
   PubMed Web of Science ®Google Scholar
• Wagener G. Assessment of hepatic function, operative candidacy, and medical management after liver resection in the patient with underlying liver disease. Semin Liver Dis. 2013;33:204–212.
   PubMed Web of Science ®Google Scholar
• Yoon JH, Choi JI, Jeong YY, et al. Pre-treatment estimation of future remnant liver function using gadoxetic acid MRI in patients with HCC. J Hepatol. 2016.
   Web of Science ®Google Scholar
• Boyer JL. Bile formation and secretion. Compr Physiol. 2013;3:1035–1078.
   PubMed Web of Science ®Google Scholar
• Boyer JL. Nuclear receptor ligands: rational and effective therapy for chronic cholestatic liver disease? Gastroenterology. 2005;129:735–740.
   PubMed Web of Science ®Google Scholar
• Boyer JL. It's all about bile. Hepatology. 2009;49:711–723.
   PubMed Web of Science ®Google Scholar
• Leonhardt M, Keiser M, Oswald S, et al. Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-DTPA: role of human organic anion transporters. Drug Metab Dispos: Biol. Fate Chemicals. 2010;38:1024–1028.
   PubMed Web of Science ®Google Scholar
• Pascolo L, Cupelli F, Anelli PL, et al. Molecular mechanisms for the hepatic uptake of magnetic resonance imaging contrast agents. Biochem Bioph Res Commun. 1999;257:746–752.
   PubMed Web of Science ®Google Scholar
• Pascolo L, Petrovic S, Cupelli F, et al. ABC protein transport of MRI contrast agents in canalicular rat liver plasma vesicles and yeast vacuoles. Biochem Bioph Res commun. 2001;282:60–66.
   PubMed Web of Science ®Google Scholar
• Tsuda N, Matsui O. Cirrhotic rat liver: Reference to transporter activity and morphologic changes in bile canaliculi–gadoxetic acid-enhanced MR imaging. Radiology. 2010;256:767–773.
   PubMed Web of Science ®Google Scholar
• van Montfoort JE, Stieger B, Meijer DK, et al. Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1. J Pharmacol Exp Ther. 1999;290:153–157.
   PubMed Web of Science ®Google Scholar
• Nishino M, Iimuro Y, Ueki T, et al.. Hepatocyte growth factor improves survival after partial hepatectomy in cirrhotic rats suppressing apoptosis of hepatocytes. Surgery. 2008;144:374–384.
   PubMed Web of Science ®Google Scholar
• Higgins GM, Anderson RM. Experimental pathology of the liver. I. Restoration of the liver of the white rat following partial surgical removal. Arch Pathol. 1931;12:186–202.
   Google Scholar
• Weinmann HJ, Ebert W, Misselwitz B, et al. Tissue-specific MR contrast agents. Eur J Radiol. 2003;46:33–44.
   PubMed Web of Science ®Google Scholar
• Ulloa JL, Stahl S, Yates J, et al. Assessment of gadoxetate DCE-MRI as a biomarker of hepatobiliary transporter inhibition. NMR Biomed. 2013;26:1258–1270.
   PubMed Web of Science ®Google Scholar
• Tsuda N, Harada K, Matsui O. Effect of change in transporter expression on gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging during hepatocarcinogenesis in rats. J Gastroen Hepatol. 2011;26:568–576.
   PubMed Web of Science ®Google Scholar
• Makino T, Ohtake N, Watanabe A, et al. Down-regulation of a hepatic transporter multidrug resistance-associated protein 2 is involved in alteration of pharmacokinetics of glycyrrhizin and its metabolites in a rat model of chronic liver injury. Drug Metab dispos: Biol Fate Chemicals. 2008;36:1438–1443.
   PubMed Web of Science ®Google Scholar
• Geier A, Dietrich CG, Voigt S, et al. Effects of proinflammatory cytokines on rat organic anion transporters during toxic liver injury and cholestasis. Hepatology. 2003;38:345–354.
   PubMed Web of Science ®Google Scholar
• Fouassier L, Beaussier M, Schiffer E, et al. Hypoxia-induced changes in the expression of rat hepatobiliary transporter genes. Am. J Physiol Gastr. Liver Physiol. 2007;293:G25–G35.
   PubMed Web of Science ®Google Scholar
• George J, Chandrakasan G. Biochemical abnormalities during the progression of hepatic fibrosis induced by dimethylnitrosamine. Clin Biochem. 2000;33:563–570.
   PubMed Web of Science ®Google Scholar
• Lagadec M, Doblas S, Giraudeau C, et al. Advanced fibrosis: Correlation between pharmacokinetic parameters at dynamic gadoxetate-enhanced MR imaging and hepatocyte organic anion transporter expression in rat liver. Radiology. 2015;274:379–386.
   PubMed Web of Science ®Google Scholar
• Saito S, Obata A, Kashiwagi Y, et al. Dynamic contrast-enhanced MRI of the liver in Mrp2-deficient rats using the hepatobiliary contrast agent Gd-EOB-DTPA. Invest Radiol. 2013;48:548–553.
   PubMed Web of Science ®Google Scholar
• Schmitz SA, Muhler A, Wagner S, et al. Functional hepatobiliary imaging with gadolinium-EOB-DTPA. A comparison of magnetic resonance imaging and 153gadolinium-EOB-DTPA scintigraphy in rats. Invest Radiol. 1996;31:154–160.
   PubMed Web of Science ®Google Scholar
• Frericks BB, Loddenkemper C, Huppertz A, et al. Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB-DTPA. AJR Am. J. Roentgenol. 2009;193:1053–1060.
   PubMed Web of Science ®Google Scholar
• Hamm B, Staks T, Muhler A, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: Safety, pharmacokinetics, and MR imaging. Radiology. 1995;195:785–792.
   PubMed Web of Science ®Google Scholar